Результаты поиска

Targeting Bone Metastases in Metastatic Castration-Resistant Prostate Cancer.

Skeletal involvement in metastatic castrate-resistant prostate cancer (mCRPC) is common and results in significant morbidity and mortality. The interaction of prostate cancer with the bone microenvironment contributes to progression of cancer in the bone leading to skeletal-related events (SREs). Studies aimed at targeting the bone have been carried out over the recent years. Bisphosphonates are synthetic pyrophosphate analogs first investigated for their role in SRE prevention with zoledronic acid as the main bisphosphonate that is approved by the US Food and Drug Administration for retardati

Совпадение в полном тексте источника
… Patients were pretreated with docetaxel, intolerant of docetaxel, or refused to take prior docetaxel. … The possibility of combining radium and docetaxel was examined in a phase 1/2a trial, and the combination was found to be safe and efficacious. 71 However, the dose of docetaxel selected for the phase 2a portion had to be reduced from 75 mg/m 2 to 60 mg/m 2 every three weeks (for 10 cycles) with the …

Analysis of patient reported outcomes included in the registrational clinical trials of nivolumab for advanced non-small cell lung cancer.

In the era of value-based oncology care, stakeholders are increasingly using patient reported outcomes (PROs) to guide clinical and regulatory decisions. PROs are also included in health technology assessments to guide patient access, drug reimbursement and pricing. We reviewed PROs collected in the United States Food and Drug Administration approved indications of nivolumab in advanced NSCLC. We analyzed the PRO data reported in the CheckMate 9LA (NCT03215706), CheckMate 227 (NCT02477826), CheckMate 057 (NCT01673867), and CheckMate 017 (NCT01642004) registrational clinical trials, and conclud

Совпадение в полном тексте источника
… The EQ-5D completion rates were 83.6% for nivolumab and 80.0% for docetaxel, respectively. … than the MID in the docetaxel group. …

Nanotechnology in Prostate Cancer: PSMA-Targeted Nanoplatforms, TME-Responsive Therapy, Immunomodulation, and Clinical Translation Challenges.

The field of nanotechnology has demonstrated considerable potential in the diagnosis and treatment of prostate cancer, particularly through the use of prostate-specific membrane antigen (PSMA)-targeted platforms and tumor microenvironment (TME)-responsive systems. In the context of diagnosis, nanoparticle-based molecular imaging probes have been shown to enhance detection sensitivity and specificity. These probes include superparamagnetic iron oxide, which is utilized in magnetic resonance imaging, and near-infrared fluorescent nanomicelles. Additionally, nanostructured liquid biopsy systems h

Совпадение в полном тексте источника
… lipid suspension (NDLS) Liposomal docetaxel (nanosomal formulation) Passive targeting (EPR) Docetaxel Phase IV, multicenter, open-label (India) Objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS) Acceptable safety profile; AEs consistent with docetaxel; no unexpected … lipid suspension (NDLS) | Liposomal docetaxel (nanosomal formulation) | Passive targeting (EPR) | Docetaxel | Phase IV, multicenter, open-label (India) | Objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS) | Acceptable safety profile; AEs consistent with docetaxel …

The Potential of Mushroom Extracts to Improve Chemotherapy Efficacy in Cancer Cells: A Systematic Review.

Chemoresistance is a challenge in cancer treatment, limiting the effectiveness of chemotherapy. Mushroom extracts have shown potential as treatments for cancer therapies, offering a possible solution to overcome chemoresistance. This systematic review aimed to explore the role of mushroom extracts in enhancing chemotherapy and reversing chemoresistance in cancer cells. We searched the PubMed, Web of Science and Scopus databases, following the PRISMA guidelines, and registered on PROSPERO. The extracts acted by inhibiting the proliferation of cancer cells, as well as enhancing the effect of che

Совпадение в полном тексте источника
… CAFs are described as inherently resistant to docetaxel [ 28 ]. … In additional experiments, it was found that CAFs are naturally resistant to docetaxel up to a concentration of 240 nM, but when treated with 0.5 mg/mL MPSSS, the sensitivity of CAFs to docetaxel increased [ 28 ]. …

Circular RNAs and Drug Resistance in Genitourinary Cancers: A Literature Review.

In recent years, systematic treatment has made great progress in genitourinary tumors. However, some patients develop resistance to the treatments, resulting in an increase in mortality. Circular RNAs (circRNAs) form a class of non-coding RNAs with high stability and significant clinical relevance. Accumulating evidence indicates that circRNAs play a vital role in cancer development and tumor chemotherapy resistance. This review summarizes the molecular and cellular mechanisms of drug resistance mediated by circRNAs to common drugs used in the treatment of genitourinary tumors. Several circRNA

Совпадение в полном тексте источника
… Docetaxel Resistance in PCa Docetaxel has been applied to CRPC since the 1990s and the mechanism behind its resistance is the most well-studied [ 110 ]. … Hsa_circ_0000735 was upregulated in docetaxel-resistant PCa and knockdown of it boosted docetaxel sensitivity, constrained viability and progression, and fostered apoptosis of docetaxel-resistant PCa cells [ 111 ]. …

Prostate cancer immunotherapy-based strategies: an updated review emphasizing immune checkpoint inhibitors.

Prostate cancer (PC) is one of the most common cancers that is diagnosed in about 10-15% of men in old age. It seems that the current treatments are not effective, and this leads to prostate cancer becoming the second-deadliest cancer. Treatments such as chemotherapy, radiotherapy, androgen deprivation therapy (ADT), and surgery are among these treatments. However, the possibility of disease recurrence after these treatments is high. Therefore, other methods have become necessary, and PC treatment is changing. One of the methods that has received much attention today is immunotherapy. Immunoth

Совпадение в полном тексте источника
… Docetaxel 3. … Docetaxel 4. …

Ядерное изображение костных метастазов в раке простаты: появление современных методов с использованием новых радиотрацеров

Точная установка рака простаты (ПХА) при начальной диагностике и при биохимических рецидивах имеет важное значение для определения прогноза и оптимальной стратегии лечения. На сегодняшний день обработка метастатической ПХА основана главным образом на результатах обычной съемки с использованием абдоминопелвича, рассчитываемого по томографии (КТ) и синтиграфии костей. Однако эти исследования имеют ограниченную чувствительность и специфичность, что ограничивает их способность точно выявлять и количественно оценивать реальные масштабы активных заболеваний. Для обнаружения ПХА были разработаны совр

Совпадение в полном тексте источника
… Docetaxel was combined with ADT in two experimental study arms: ADT plus docetaxel ( n = 592) and ADT, docetaxel and zoledronic acid ( n = 593). … The incidence of adverse events grade ≥ 3 was 52% in both docetaxel containing arms (versus 32% in the two non-docetaxel containing arms). …

Wisely frugal: ensuring sustainable funding for novel cancer therapeutics through a budget impact analysis in resource-limited settings.

IntroductionCancer care in Sri Lanka is predominantly provided through its state health system which is free at the point of delivery. We performed a budget impact analysis of novel cancer drugs with a view to enabling better prioritising of their procurement.MethodsMedian survival gain was obtained for each indication of a novel cancer drug by a review of the literature. The direct cost of drug procurement was obtained from the Ministry of Health of Sri Lanka and the cost per life year gained was computed for each indication. Two thresholds - per capita gross domestic product (GDP) per life y

Совпадение в полном тексте источника
… Cabazitaxel in the treatment of metastatic castration resistant prostate cancer (post-docetaxel). Fulvestrant in the first and second line treatment of endocrine sensitive metastatic breast cancer. … Abiraterone 1000 mg | Metastatic castration resistant prostate cancer pre docetaxel | Lancet Oncol. 2015 Feb;16(2):152–60. …

Overcoming Drug Resistance in Advanced Prostate Cancer by Drug Repurposing.

Prostate cancer (PCa) is the second most common cancer in men. Common treatments include active surveillance, surgery, or radiation. Androgen deprivation therapy and chemotherapy are usually reserved for advanced disease or biochemical recurrence, such as castration-resistant prostate cancer (CRPC), but they are not considered curative because PCa cells eventually develop drug resistance. The latter is achieved through various cellular mechanisms that ultimately circumvent the pharmaceutical's mode of action. The need for novel therapeutic approaches is necessary under these circumstances. An

Совпадение в полном тексте источника
… + Estramustine + Hydrocortisone Versus Docetaxel + Prednisone in Patients with Advanced PCa (PROSTATA) | NCT00705822 | III | 1 August 2006 | 54 | Terminated | Docetaxel + prednisone vs. docetaxel + estramusine + hydrocortisone Steroid | Docetaxel, Prednisone, and Vatalanib in Treating Patients with … | Abiraterone acetate + glucocorticoid Steroid | An Open-Label Study of YM155 + Docetaxel in Subjects with Advanced Hormone Refractory PCa and Other Solid Tumors | NCT00514267 | I/II | 1 May 2007 | 32 | Completed | YM 155 + docetaxel + prednisone vs. …

Oblimersen: Augmerosen, BCL-2 antisense oligonucleotide - Genta, G 3139, GC 3139, oblimersen sodium.

Oblimersen is an antisense oligonucleotide developed by Genta for systemic use as an injection. It comprises a phosphorothioate backbone lin … announced the presentation of clinical data from a phase II trial of oblimersen in combination with docetaxel injection concentrate for patients with advanced HRPC. Researchers reported that these findings validated progression into phase III trials. Genta has licensed eight US patents relating to oblimersen and its backbone chemistry and these expire betwe …

Pancreatic cancer: chemotherapy and radiotherapy.

Pancreatic cancer in many cases appears in a non-curatively resectable stage when the diagnosis is made. Palliative treatment become an option in the patients with advanced stage. The present article reviewed chemotherapy and radiotherapy in various advanced stage of pancreatic cancer.

Совпадение в полном тексте источника
… docetaxel regimen (docetaxel at 75 mg/m 2 or docetaxel-gemcitabine-capecitabine or docetaxel-gemcitabine) until progressive disease. … Docetaxel dose intensity was 90 percent in the patients who received weekly docetaxel, 85% in docetaxel-erlotinib regimen and 65% in 3-weekly regimen (docetaxel-gemcitabine-capecitabine,docetaxel-gemcitabine). …

Trial Watch: Tumor-targeting monoclonal antibodies in cancer therapy.

In 1997, for the first time in history, a monoclonal antibody (mAb), i.e., the chimeric anti-CD20 molecule rituximab, was approved by the US Food and Drug Administration for use in cancer patients. Since then, the panel of mAbs that are approved by international regulatory agencies for the treatment of hematopoietic and solid malignancies has not stopped to expand, nowadays encompassing a stunning amount of 15 distinct molecules. This therapeutic armamentarium includes mAbs that target tumor-associated antigens, as well as molecules that interfere with tumor-stroma interactions or exert direct

Совпадение в полном тексте источника
… Bevacizumab | VEGF | Angiosarcoma and epithelioid hemangioendotheliomas | II | As a single agent | 154 Breast carcinoma | n.a. | Coupled to 89 Zr as a diagnostic tool | 155 II | Combined with docetaxel plus capecitabine | 126 II | Combined with docetaxel plus cisplatin | 128 II | Combined with gemcitabine … | 129 II | Combined with trastuzumab plus docetaxel | 48 III | Combined with docetaxel | 125 III | Combined with capecitabine or paclitaxel | 130 III | Combined with capecitabine or paclitaxel | 127 III | Combined with trastuzumab plus docetaxel | 156 Cervical cancer | II | Combined with topotecan plus …

Allergy in Cancer Care: Antineoplastic Therapy-Induced Hypersensitivity Reactions.

As the backbone of oncological treatments, systemic chemotherapy is still one of the main pawns in cancer care, alone or in combination with newer targeted agents. All chemotherapy agents can be associated with a type of adverse event called an infusion reaction, which can be characterized as unpredictable, non-dose related, and unexplained by the cytotoxic profile of the drug. For some of these events, a certain immunological mechanism can be identified by blood or skin testing. In this case, we can speak of true hypersensitivity reactions that occur as a response to an antigen/allergen. The

Совпадение в полном тексте источника
… Concerning the immediate docetaxel-induced HSR, most of the works indicate a non-allergic nature of these events [ 65 ]. … As with docetaxel, the main cause for the reactions is thought to be the emulsifier Polysorbate 80 [ 71 ]. …

Drug repurposing in KRAS G12C-mutant NSCLC: a focus on resistance mechanisms and clinical strategies.

KRAS G12C-mutant non-small cell lung cancer (NSCLC) has transitioned from a therapeutically problematic disease to a precision-targetable cancer, anchored by the landmark approvals of sotorasib and adagrasib. Yet despite these advances, responses remain limited in duration and multiple mechanisms of rapid adaptive resistance emerge under inhibitor pressure. These resistance mechanisms define a therapeutic vulnerability map that can be addressed by repurposing approved agents with established safety profiles. This review emphasises the current understanding of KRAS G12C biology, integrates upda

Совпадение в полном тексте источника
… However, the trial failed to display an OS benefit of 10.6 months with sotorasib vs. 11.3 months with docetaxel (HR: 1.01; 95% CI: 0.77–1.33) numerically favouring docetaxel, although the study was not powered for OS and permitted crossover. … versus docetaxel in KRASG12C-mutated non-small-cell lung cancer (KRYSTAL-12): a randomised, open-label, phase 3 trial. …

Association of Immune Checkpoint Inhibitors With Neurologic Adverse Events: A Systematic Review and Meta-analysis.

ImportanceNeurologic adverse events (NAEs) due to immune checkpoint inhibitors (ICIs) can be fatal but are underexplored.ObjectiveTo compare NAEs reported in randomized clinical trials (RCTs) of US Food and Drug Administration-approved ICIs with other forms of chemotherapy and placebo.Data sourcesBibliographic databases (Embase, Ovid, MEDLINE, and Scopus data) and trial registries (ClinicalTrials.gov) were searched from inception through March 1, 2020.Study selectionPhase II/III RCTs evaluating the use of ICIs were eligible for inclusion. Unpublished trials were excluded from the analysis.Data

Совпадение в полном тексте источника
… Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med. 2015;373(17):1627-1639. doi: 10.1056/NEJMoa1507643 62. Eggermont AM, Chiarion-Sileni V, Grob JJ, et al. … Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial. …

The role and mechanisms of action of microRNAs in cancer drug resistance.

MicroRNAs (miRNAs) are small non-coding RNAs with a length of about 19-25 nt, which can regulate various target genes and are thus involved in the regulation of a variety of biological and pathological processes, including the formation and development of cancer. Drug resistance in cancer chemotherapy is one of the main obstacles to curing this malignant disease. Statistical data indicate that over 90% of the mortality of patients with cancer is related to drug resistance. Drug resistance of cancer chemotherapy can be caused by many mechanisms, such as decreased antitumor drug uptake, modified

Совпадение в полном тексте источника
… Silencing miRNA-650 could increase the in vitro sensitivity of resistant LAD cells to docetaxel, whereas upregulation of miRNA-650 decreased the sensitivity of parental LAD cells to docetaxel both in vitro and in vivo. … Ectopic expression of miRNA-200b could reverse the resistance of NSCLC to docetaxel. MiRNA-200b can also regulate the resistance of SCLC to chemotherapeutic drugs. …

A technical note on emerging combination approach involved in the onconanotherapeutics.

Cancer is the second cause of mortality worldwide, and the currently available conventional treatment approach is associated with serious side effects and poor clinical outcomes. Based on the outcome of the exploratory preclinical and clinical studies, it was found that therapeutic response increases multiple folds when anticancer drugs are used in combination. However, the conventional combination of anticancer drugs was associated with various limitations such as increased cost of treatment, systemic toxicity, drug resistance, and reduced pharmacokinetic attributes. Hence, attempts were made

Совпадение в полном тексте источника
… Another clinical study revealed a promising tumor treatment competency of actively targeted polymeric NPs containing the chemotherapeutic docetaxel in comparison to a solvent-based docetaxel formulation (Hrkach et al., 2012 ). … The outcomes showed a limited synergy when both docetaxel and ionizing radiation were used by either genetic or pharmacological pathway. Docetaxel and bortezomib, collectively led to a decreased in vitro invasion in only 8505C cells. …

Biomarkers of Chemotherapy-Induced Peripheral Neuropathy: Current Status and Future Directions.

Chemotherapy induced peripheral neuropathy (CIPN) is an often severe and debilitating complication of multiple chemotherapeutic agents that can affect patients of all ages, across cancer diagnoses. CIPN can persist post-therapy, and significantly impact the health and quality of life of cancer survivors. Identifying patients at risk for CIPN is challenging due to the lack of standardized objective measures to assess for CIPN. Furthermore, there are no approved preventative treatments for CIPN, and therapeutic options for CIPN remain limited once it develops. Biomarkers of CIPN have been studie

Совпадение в полном тексте источника
… | CTCAE | ( 46 ) | CYP2C8 | rs10509681 | Paclitaxel | CTCAE | ( 47 ) | | rs1058930 | Paclitaxel | CTCAE | ( 42 ) | CYP1B1 | rs1056836 | Paclitaxel | CTCAE | ( 42 ) | NR1I3 | rs11584174 | Paclitaxel | CTCAE | ( 48 ) | UGT2B7 | rs7662029 | Docetaxel | CTCAE | ( 48 ) | | rs7438284 | Docetaxel | … CTCAE | ( 48 ) | | rs7439366 | Docetaxel | CTCAE | ( 48 ) | | rs7668258 | Docetaxel | CTCAE | ( 48 ) | ABCB1 | rs3213619 | Paclitaxel | CTCAE | ( 42 ) | | rs4728709 | Vincristine | CTCAE | ( 44 ) | | rs1128503 | Paclitaxel, docetaxel | CTCAE | ( 46 ) | | rs1045642 | Paclitaxel | CTCAE | ( …

Targeted Palliative Radionuclide Therapy for Metastatic Bone Pain.

Bone metastasis develops in multiple malignancies with a wide range of incidence. The presence of multiple bone metastases, leading to a multitude of complications and poorer prognosis. The corresponding refractory bone pain is still a challenging issue managed through multidisciplinary approaches to enhance the quality of life. Radiopharmaceuticals are mainly used in the latest courses of the disease. Bone-pain palliation with easy-to-administer radionuclides offers advantages, including simultaneous treatment of multiple metastatic foci, the repeatability and also the combination with other

Совпадение в полном тексте источника
… Repeated doses of [ 186 Re]Re–HEDP combined with docetaxel and prednisone versus docetaxel and prednisone alone have shown no significant improvement in PFS nor pain scores in 88 mCRPC patients [ 100 ]. … In addition, the concomitant treatment with docetaxel and [ 223 Ra]RaCl, compared to docetaxel, has demonstrated a favorable antitumor activity has prolonged biochemical suppression [ 138 ] and time to progression [ 139 ]. …

Assessing the Therapeutic Role of Rehabilitation Programs in Chemotherapy-Induced Peripheral Neuropathy (CIPN)-A Scoping Review.

Background: Chemotherapy-induced peripheral neuropathy (CIPN) is a common, debilitating side effect of cancer treatment. Characterized by symptoms like pain, numbness, and muscle weakness, CIPN significantly impacts patients' quality of life. Current management strategies vary, with limited consensus on effective treatments. This scoping review aims to explore comprehensive rehabilitation interventions for CIPN, focusing on enhancing patient well-being and functional abilities. Methods: A scoping review, guided by Arksey and O'Malley's framework and Levac et al.'s refinements, was conducted to

Совпадение в полном тексте источника
… + cyclophosphamide): 1 (3%)TA (docetaxel + doxorubicin): 2 (6%) TC (docetaxel + cyclophosphamide): 12 (33%) CMF (cyclophosphamide + methotrexate + 5-FU): 4 (11%) | TAC (docetaxel + doxorubicin + cyclophosphamide): 2 (6%)AC (doxorubicin + cyclophosphamide) + mt(docetaxel): 14 (39%)AC (doxorubicin + cyclophosphamide … , carboplatin) at least 3 months before enrollment | Completed neurotoxic chemotherapy (eg, paclitaxel, docetaxel, carboplatin) at least 3 months before enrollment | Neurotoxic chemotherapy (eg, paclitaxel, docetaxel, carboplatin) | Neurotoxic chemotherapy (eg, paclitaxel, docetaxel, carboplatin) | Breast …